苑東生物(688513.SH):富馬酸比索洛爾片(蘇萊樂®)的發明專利"一種富馬酸比索洛爾I晶型及其製備方法"榮獲中國專利優秀獎
格隆匯6月8日丨苑東生物(688513.SH)公佈,近日,國家知識產權局發佈《國家知識產權局關於第二十五屆中國專利獎授獎的決定》(國知發運字〔2025〕20號),成都苑東生物製藥股份有限公司(以下簡稱“公司”)富馬酸比索洛爾片(蘇萊樂®)的發明專利“一種富馬酸比索洛爾I晶型及其製備方法”榮獲第二十五屆中國專利優秀獎。
專利是藥企的核心資產之一,也是保護創新成果、維持市場競爭優勢的關鍵。本次公司富馬酸比索洛爾片的發明專利獲得第二十五屆中國專利優秀獎,是對公司在創新藥物研發和知識產權保護方面所做努力的高度認可,也體現了該藥物在技術先進性、創新性和臨牀價值等方面的顯著優勢。
截至2024年12月31日,公司累計申請專利425項(含發明專利408項),其中已獲授權專利156項(含發明專利142項)。未來,公司將繼續秉持以創新為先導,以知識產權管理為保障的理念,強化專利佈局,努力研製出更多高質量的創新藥品,為服務健康中國、造福全球患者貢獻力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.